聚腺苷二磷酸核糖聚合酶抑制剂（PARPi）的出现给卵巢癌治疗领域带来了重大变革。然而，2022 年，由于不良事件可能性增加，Rucaparib、Olaparib 和 Niraparib 的三线及后续疗法的上市批准被撤销。因此，探索新的治疗方式仍然刻不容缓。最近，PARPi 与免疫检查点抑制剂 (ICIs) 的整合已成为卵巢癌的潜在治疗选择。本文对 PARPi 和 ICI 在卵巢癌治疗中的机制和应用进行了全面的研究。它综合了支持其组合使用的现有证据，并讨论了在持续开发工作中值得关注的关键考虑因素。© 2024。作者。

The advent of polyadenosine diphosphate ribose polymerase inhibitors (PARPi) has brought about significant changes in the field of ovarian cancer treatment. However, in 2022, Rucaparib, Olaparib, and Niraparib, had their marketing approval revoked for third-line and subsequent therapies due to an increased potential for adverse events. Consequently, the exploration of new treatment modalities remains imperative. Recently, the integration of PARPi with immune checkpoint inhibitors (ICIs) has emerged as a potential remedy option within the context of ovarian cancer. This article offers a comprehensive examination of the mechanisms and applications of PARPi and ICIs in the treatment of ovarian cancer. It synthesizes the existing evidence supporting their combined use and discusses key considerations that merit attention in ongoing development efforts.© 2024. The Author(s).